BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 22508345)

  • 1. Neonatal screening: identification of children with 11β-hydroxylase deficiency by second-tier testing.
    Janzen N; Riepe FG; Peter M; Sander S; Steuerwald U; Korsch E; Krull F; Müller HL; Heger S; Brack C; Sander J
    Horm Res Paediatr; 2012; 77(3):195-9. PubMed ID: 22508345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
    Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
    Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
    J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China.
    Zhan X; Han L; Qiu W; Gu X; Guo J; Chang S; Wang Y; Zhang H
    Steroids; 2022 Sep; 185():109056. PubMed ID: 35660382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of 11beta-hydroxylase deficiency detected in a newborn screening program by second-tier LC-MS/MS.
    Peter M; Janzen N; Sander S; Korsch E; Riepe FG; Sander J
    Horm Res; 2008; 69(4):253-6. PubMed ID: 18204274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: Outcomes of Extended Pilot Study in 241,083 Infants.
    Güran T; Tezel B; Çakır M; Akıncı A; Orbak Z; Keskin M; Selver Eklioğlu B; Ozon A; Özbek MN; Karagüzel G; Hatipoğlu N; Gürbüz F; Çizmecioğlu FM; Kara C; Şimşek E; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2020 Sep; 12(3):287-294. PubMed ID: 32157855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
    Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
    Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia.
    Tieh PY; Yee JK; Hicks RA; Mao CS; Lee WN
    J Perinatol; 2017 Mar; 37(3):283-287. PubMed ID: 27929529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of a steroid profile in heel prick blood using LC-MS/MS.
    Boelen A; Ruiter AF; Claahsen-van der Grinten HL; Endert E; Ackermans MT
    Bioanalysis; 2016; 8(5):375-84. PubMed ID: 26891684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry.
    Lacey JM; Minutti CZ; Magera MJ; Tauscher AL; Casetta B; McCann M; Lymp J; Hahn SH; Rinaldo P; Matern D
    Clin Chem; 2004 Mar; 50(3):621-5. PubMed ID: 14656905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening.
    Monostori P; Szabó P; Marginean O; Bereczki C; Karg E
    Horm Res Paediatr; 2015; 84(5):311-8. PubMed ID: 26397944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.
    Minutti CZ; Lacey JM; Magera MJ; Hahn SH; McCann M; Schulze A; Cheillan D; Dorche C; Chace DH; Lymp JF; Zimmerman D; Rinaldo P; Matern D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3687-93. PubMed ID: 15292289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency detected by neonatal screening.
    Liu SY; Lee CT; Tung YC; Chien YH; Hwu WL; Tsai WY
    J Formos Med Assoc; 2018 Feb; 117(2):126-131. PubMed ID: 28392195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The High Relevance of 21-Deoxycortisol, (Androstenedione + 17α-Hydroxyprogesterone)/Cortisol, and 11-Deoxycortisol/17α-Hydroxyprogesterone for Newborn Screening of 21-Hydroxylase Deficiency.
    Watanabe K; Tsuji-Hosokawa A; Hashimoto A; Konishi K; Ishige N; Yajima H; Sutani A; Nakatani H; Gau M; Takasawa K; Tajima T; Hasegawa T; Morio T; Kashimada K
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3341-3352. PubMed ID: 36071550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia.
    Cavarzere P; Samara-Boustani D; Flechtner I; Dechaux M; Elie C; Tardy V; Morel Y; Polak M
    Eur J Endocrinol; 2009 Aug; 161(2):285-92. PubMed ID: 19451212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in the pre-screening era.
    Lee CT; Tung YC; Hsiao PH; Lee JS; Tsai WY
    J Formos Med Assoc; 2010 Feb; 109(2):148-55. PubMed ID: 20206839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience.
    Schwarz E; Liu A; Randall H; Haslip C; Keune F; Murray M; Longo N; Pasquali M
    Pediatr Res; 2009 Aug; 66(2):230-5. PubMed ID: 19390483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional glucocorticoid receptor gene variants do not underlie the high variability of 17-hydroxyprogesterone screening values in healthy newborns.
    Schreiner F; Tozakidou M; Maslak R; Holtkamp U; Peter M; Gohlke B; Woelfle J
    Eur J Endocrinol; 2009 Apr; 160(4):667-73. PubMed ID: 19174530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum 21-Deoxycortisol, 17-Hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency.
    Tonetto-Fernandes V; Lemos-Marini SH; Kuperman H; Ribeiro-Neto LM; Verreschi IT; Kater CE
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2179-84. PubMed ID: 16551734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.